Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Indore, 453552, MP, India.
Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Inflamm Res. 2024 Oct;73(10):1645-1656. doi: 10.1007/s00011-024-01921-5. Epub 2024 Jul 25.
Inflammation, a biological response of the immune system, can be triggered by various factors such as pathogens, damaged cells, and toxic compounds. These factors can lead to chronic inflammatory responses, potentially causing tissue damage or disease. Both infectious and non-infectious agents, as well as cell damage, activate inflammatory cells and trigger common inflammatory signalling pathways, including NF-κB, MAPK, and JAK-STAT pathways. These pathways are activated through adaptor proteins, which possess distinct protein binding domains that connect corresponding interacting molecules to facilitate downstream signalling. Adaptor molecules have gained widespread attention in recent years due to their key role in chronic inflammatory diseases.
In this review, we explore potential pharmacological agents that can be used to target adaptor molecules in chronic inflammatory responses. A comprehensive analysis of published studies was performed to obtain information on pharmacological agents.
This review highlights the therapeutic strategies involving small molecule inhibitors, antisense oligonucleotide therapy, and traditional medicinal compounds that have been found to inhibit the inflammatory response and pro-inflammatory cytokine production. These strategies primarily block the protein-protein interactions in the inflammatory signaling cascade. Nevertheless, extensive preclinical studies and risk assessment methodologies are necessary to ensure their safety.
炎症是免疫系统的一种生物反应,可以由病原体、受损细胞和有毒化合物等多种因素触发。这些因素可能导致慢性炎症反应,从而导致组织损伤或疾病。感染和非感染因子以及细胞损伤都会激活炎症细胞,并触发常见的炎症信号通路,包括 NF-κB、MAPK 和 JAK-STAT 通路。这些途径通过衔接蛋白激活,这些蛋白具有独特的蛋白结合域,将相应的相互作用分子连接起来,以促进下游信号转导。衔接分子近年来受到广泛关注,因为它们在慢性炎症性疾病中起着关键作用。
在这篇综述中,我们探讨了潜在的药理学制剂,这些制剂可以用于针对慢性炎症反应中的衔接分子。对已发表的研究进行了全面分析,以获取有关药理学制剂的信息。
本综述强调了涉及小分子抑制剂、反义寡核苷酸治疗和传统药用化合物的治疗策略,这些策略已被发现可抑制炎症反应和促炎细胞因子的产生。这些策略主要阻断炎症信号级联中的蛋白-蛋白相互作用。然而,需要进行广泛的临床前研究和风险评估方法,以确保其安全性。